{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:29:45Z","timestamp":1765758585705},"reference-count":0,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[1980,7,1]],"date-time":"1980-07-01T00:00:00Z","timestamp":331257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[1980,7]]},"abstract":"<jats:p>\n            The assay for serum antibody to the\n            <jats:italic>Salmonella typhi<\/jats:italic>\n            capsular polysaccharide (Vi) antigen has recently been revised because of the availability of a purified, highly polymerized Vi antigen. We compared this revised Vi antibody assay to the traditional one for potential usefulness in the surveillance of chronic enteric carriers of\n            <jats:italic>S. typhi.<\/jats:italic>\n            The purified Vi antigen of\n            <jats:italic>Citrobacter freundii<\/jats:italic>\n            was incorporated into a passive hemagglutination assay for serum Vi antibody; the standard Vi antibody assay was also a hemagglutination assay that employed as the Vi antigen a crude extract of\n            <jats:italic>Citrobacter<\/jats:italic>\n            (Ballerup O group 29). As determined by the revised assay, Vi antibody was found in the sera of 22 (71%) of 31 current typhoid carriers, none of 6 resolved carriers, and none of 22 control subjects. According to the traditional assay, Vi antibody was present in 23 of those current carriers (74%), 1 of the resolved carriers (17%), and 4 of the control subjects (18%). The rate of false-positive Vi antibody tests among resolved carriers and control subjects was less with the revised assay (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). Successful antimicrobial therapy resulted in a reversion to seronegativity within 1 year in 8 of 10 Vipositive carriers according to the revised assay, but in only 3 of 11 according to the standard assay (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). During a 2-year period of observation, 15 (94%) of 16 current typhoid carriers had at least one positive purified Vi antibody test; among 12 of those patients with Vi titers of 1:40 or greater, 9 (75%) were continuously Vi positive. Thus, the revised Vi antibody assay is more specific and no less sensitive than the standard assay for the condition of current enteric carriage of\n            <jats:italic>S. typhi.<\/jats:italic>\n            This serological test could be of value in the surveillance of typhoid carriers by public health agencies.\n          <\/jats:p>","DOI":"10.1128\/jcm.12.1.22-26.1980","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T02:25:13Z","timestamp":1578191113000},"page":"22-26","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":40,"title":["Evaluation of a New Assay for Vi Antibody in Chronic Carriers of\n            <i>Salmonella typhi<\/i>"],"prefix":"10.1128","volume":"12","author":[{"given":"Charles M.","family":"Nolan","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Arkansas College of Medicine, Little Rock, Arkansas 72205"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Feeley","sequence":"additional","affiliation":[{"name":"Center for Disease Control, Atlanta, Georgia 30333"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Paul C.","family":"White","sequence":"additional","affiliation":[{"name":"Arkansas Department of Health, Little Rock, Arkansas 72205"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith A.","family":"Hambie","sequence":"additional","affiliation":[{"name":"Center for Disease Control, Atlanta, Georgia 30333"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Brown","sequence":"additional","affiliation":[{"name":"Center for Disease Control, Atlanta, Georgia 30333"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwei-Hay","family":"Wong","sequence":"additional","affiliation":[{"name":"Center for Disease Control, Atlanta, Georgia 30333"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.12.1.22-26.1980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.12.1.22-26.1980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T12:26:40Z","timestamp":1646483200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.12.1.22-26.1980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1980,7]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1980,7]]}},"alternative-id":["10.1128\/jcm.12.1.22-26.1980"],"URL":"https:\/\/doi.org\/10.1128\/jcm.12.1.22-26.1980","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1980,7]]},"assertion":[{"value":"1980-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}